GALT

Galectin TherapeuticsA

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-07-18

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$11.00

+163.5% vs current

Most likely

Base case

50%

Probability

Target price

$5.25

+25.7% vs current

B-

Bear case

25%

Probability

Target price

$2.50

-40.1% vs current

AI sentiment snapshot

Latest data as of 2026-07-17

AI commentary

News tone is positive after the June 23 FDA update and reported roughly 22% share-price surge, but the catalyst appears substantially priced in. No social context or analyst revision data is available, and no reliable direct peer set is available. The deterministic prior remains negative over 5-, 20-, 60-, and 120-day horizons, favoring cautious monitoring rather than chasing the move.

RankAlpha Sentiment Codex - 2026-07-17

Open full AI memo

Evidence flagged

peer set is too generic or lacks enough direct operating comparators; small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report

Impact

tentative

Confidence

AI events

2026-06-23eventFDA Type C meeting aligned Phase 3 endpoint and regulatory path [#SEC-8K-2026-06-23]High impact

Galectin reported FDA alignment on the primary composite endpoint, centralized endoscopy review, a planned single 2 mg dose, and a traditional full-approval pathway for belapectin in MASH cirrhosis with portal hypertension. A recent secondary news item reported a roughly 22% share-price surge after the update.

2026-10-15catalystRunway and financing risk before Phase 3 execution [#SEC-8K-2026-03-31]High impact

The company disclosed an additional $10 million line of credit from its chairman intended to extend projected cash runway through April 2027. Financing needs and development execution remain material risks for a small-cap biotech.

2027-07-17catalystPlanned Phase 3 protocol submission in Q3 2026 [#SEC-8K-2026-06-23]High impact

The company expects to submit the final Phase 3 protocol in Q3 2026 and is preparing a registration study broadly comparable in size to NAVIGATE.

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-07-17 • Updated nightlySource: Internal modelMethodology